result of a single nucleotide change in the patient's genomic DNA (C10873T), leaving 1.6% of dystrophin gene product unsynthesized at the C terminus. Dystrophin mRNA analysis did not show rescue of the nonsense mutation as a result of exonskipping by an alternative splicing mechanism. This is the first report of an asymptomatic dystrophinopathy with a nonsense mutation in the dystrophin gene. The severe Duchenne muscular dystrophy (DMD) and the more benign Becker muscular dystrophy (BMD) are allelic conditions characterized by progressive muscular degeneration and wasting accompanied by an elevation of serum creatine kinase (CK). DMD is a rapidly progressive disease, with those affected starting to show muscle weakness at~4 -5 y of age and losing the ability to walk independently before the age of 12 y. BMD has a slower rate of progression; affected individuals remain ambulatory beyond the age of 16 y, and a few may lead near-normal lives (1) .
DMD and BMD are caused by mutation of the dystrophin gene, which encodes a 14-kb mRNA that consists of 79 exons. The gene is the largest in humans and covers Ͼ3000 kb on the X chromosome (2, 3) . DMD and BMD are the most common genetic muscle diseases, affecting Ͼ1 in 3,500 male births. Two thirds of DMD/ BMD patients have deletion or duplication mutations of the dystrophin gene, and their clinical progression can be predicted by whether the deletion or duplication maintains (in-frame) or disrupts (out-of-frame) the translational reading frame (the readingframe rule) (4). Dystrophin is absent from skeletal muscle of DMD, because the dystrophin that is produced is truncated as a result of the premature stop codon and therefore is unstable, whereas in BMD, dystrophin that contains internal in-frame deletions produces protein that can be detected (5) .
Single-base nonsense mutations have been suspected in DMD patients who do not show deletion/duplication mutations. However, detection of such defects in individual DMD patients is very difficult as a result of the large size of the gene. More than 100 nonsense mutations have been reported at various points over a 14-kb length of the dystrophin mRNA (http://www.dmd.nl). Despite this wide variation in coding potential (0 -98.6% of the full-length protein), these truncating mutations are associated with a surprisingly uniform severity of the DMD phenotype (6) . However, a limited number of single-base nonsense mutations have been reported in patients with mild BMD that showed skipping of the exon encoding the mutation, thus producing an in-frame mRNA (7-11).
Dystrophin is a cytoskeletal protein that is implicated in membrane stability and in communication between the extracellular matrix and the inner cytoskeleton (12, 13) . The protein, which consists of 3685 amino acids, is divided into four distinct domains: an N-terminal domain, a large rod-like domain of 24 spectrin-like repeats that occupies Ͼ70% of its length, a cysteine-rich domain, and, finally, a C-terminal domain (2, 14) . Studies conducted on DMD/BMD patients suggest that the N-terminal, cysteine-rich, and C-terminal domains are essential for dystrophin's function (15, 16) . Notably, the C-terminal domain, which consists of 416 amino acids encoded by 13 exons, shows sequence similarity with only two other dystrophin-related proteins and is considered to exert dystrophin's specific function (14, 17, 18) . In fact, in-frame deletions that extend into the C-terminal domain have been reported to result in DMD, whereas large in-frame deletions of the rod domain result in BMD (16) .
Here we report a C-terminally truncated dystrophin caused by a mutation in an asymptomatic boy with high CK activity. We propose that nonsense mutations of the dystrophin gene can result in a wide variety of clinical phenotypes.
METHODS

Case.
The proband (KUDN 02765682) was an 8-y-old boy. His family history disclosed no neuromuscular disease. He started to walk independently at 1 y of age, and his motor development was normal. He had a history of transient muscle weakness. At the age of 3 y, he complained of pain in the lower legs without any predisposing signs or symptoms and lost the ability to stand up and walk by himself. His serum CK was found to be 4901 IU/L (normal Ͻ169 IU/L). The muscle weakness persisted for 1 wk but disappeared spontaneously and completely.
During the following period, his serum CK remained elevated but showed a strong fluctuation in value, ranging from 1,607 to 21,100 IU/L. Despite his high CK, he did not show any muscle weakness. At the age of 5 y, he was referred to Kobe University Hospital for examination of his elevated serum CK activity. His mental development was normal. On physical examination, there was no Gower's sign, walking abnormality, or pseudohypertrophy of the legs. An electromyogram disclosed myogenic changes. A chest x-ray, electrocardiography, and echocardiography failed to reveal cardiac abnormalities. To clarify the cause of the elevation in serum CK and myogenic pattern in electromyogram, a quadriceps muscle biopsy was carried out after obtaining informed consent. The protocols of this study were approved by our ethical committee.
Immunohistochemical analysis. The muscle biopsy sample was examined pathologically and immunohistochemically. An indirect immunofluorescence analysis was performed using three dystrophin antibodies that recognize the N-terminal (NCL-Dys3), the rod (NCL-Dys1), and the C-terminal (NCLDys2) domains of dystrophin (Novocastra Laboratories, Newcastle upon Tyne, UK) (5, 19) . Furthermore, utrophin, ␤-dystroglycan, ␥-sarcoglycan (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK), laminin ␣2 (Chemicon International Inc., Temecula, CA), and ␣-dystroglycan (Upstate Biotechnology, Lake Placid, NY) were also stained using their respective antibodies. Control skeletal muscle tissue was obtained with informed consent and was simultaneously stained with the same panel of antibodies. Western blot analysis of dystrophin using an MAb that recognizes the C-terminal domain was performed by Athena Diagnostics (Worcester, MA).
Analysis of the dystrophin gene. For mutational analysis of the dystrophin gene, blood samples were obtained from the index case and family members after obtaining informed consent. DNA was isolated by standard phenol-chloroform extraction methods. For screening for deletion mutations, 19 deletion-prone exons were amplified from the genomic DNA by PCR essentially according to methods described previously (20) . Southern blot analysis using dystrophin cDNA as a probe was performed with HindIII restriction enzyme-digested DNA as a template, as described by Koenig et al. (21) . For analyzing genomic mutations, the region that encompasses exon 76 was amplified by PCR with g76F:5'-GGAGGGCTTCTAAAG-TAGG-3' as the forward primer and g76r:5'-ATGTCCCTG-TAATACGACTCTACC-3' as the reverse primer under conditions described elsewhere (20) .
Analysis of dystrophin mRNA. Reverse-transcription PCR (RT-PCR) was used to analyze the dystrophin mRNA expressed in lymphocytes or skeletal muscle as described by Roberts et al. (22, 23) . Full-length dystrophin cDNA was amplified as 10 separate, partially overlapping fragments and sequenced directly. For obtaining a fragment showing aberrant splicing, including exon 76 skipping, a region that encompasses exons 70 -79 was amplified using a forward primer corresponding to a segment of exon 70 (70f:5'-CAGGAGAAGATGTTC-GAGAC-3') and a reverse primer complementary to a segment of exon 79 (5f:5'-ATCATCTGCCATGTGGAAAAG-3').
Sequencing of the amplified product. The amplified product was purified and subjected to sequencing either directly or after subcloning into a pT7 blue T vector (Novagen, Madison, WI) (24) . The DNA sequence was determined using an automated DNA sequencer (model 373A; Applied Biosystems, Foster City, CA).
RESULTS
For elucidating the cause of the elevation in serum CK, the biopsied muscle sample was examined pathologically. Microscopic examination disclosed slight dystrophic changes such as size variation in muscle fibers, fibers with central nuclei, and degenerated and regenerated fibers. Immunofluorescence staining for dystrophin revealed a complete absence of C-terminal domain labeling (Fig. 1) . In contrast, both N-terminal and rod-domain staining was weak, patchy, and discontinuous along the plasma membrane (Fig. 1) . These findings clearly indicated dystrophinopathy, but the patterns of dystrophin staining were not typical for either DMD or BMD. Western blot analysis of dystrophin using an antibody that recognizes the C-terminal domain of dystrophin revealed no significant bands (data not shown). These staining patterns indicate that a nonsense mutation in dystrophin is present in this patient, leading to production of a protein truncated somewhere up-740 stream of the C-terminal epitope recognized by the aforementioned antibody.
For clarifying the molecular pathogenesis of the abnormal dystrophin, the dystrophin gene was scanned for mutations. Neither PCR amplification of 19 selected exons nor Southern blot analysis of the dystrophin gene revealed any gross gene rearrangements. The possibility of deletion mutation therefore seemed unlikely. To find a single-base mutation, we analyzed dystrophin mRNA extracted from peripheral lymphocytes using RT-PCR as described previously (22) . Ten fragments covering the full-length dystrophin cDNA could be amplified as normal-sized products. Direct sequencing of a fragment that encompasses exons 70 -79 disclosed a single nucleotide change: a transition from a cytosine to a thymine at nucleotide 10873 (C10873T) in exon 76 (14) . The same nucleotide change (C10873T) was present not only in his muscle dystrophin mRNA (Fig. 2) but also in his genomic DNA (data not shown) (25) . His mother was found to be a carrier of the same mutation (data not shown). Because sequencing of other fragments of dystrophin cDNA disclosed no other significant nucleotide changes, it was concluded that this mutation (C10873T) is the cause of the dystrophinopathy. The nucleotide change converted a CAG codon, which encodes glutamine at the 3625th amino acid position, to a stop TAG codon (Q3625X; Fig. 2 ). Therefore, a truncated dystrophin lacking 60 amino acids at its C terminus (1.6% of the total dystrophin sequence) was expected to be produced.
This truncation of dystrophin is compatible with the failure of the C-terminus-specific antibody to label the protein (Fig.  1) , because this antibody recognizes amino acids 3669 -3685, an epitope that is downstream of the premature stop codon (Q3625X). However, that dystrophin did stain positively with antibodies against its N-terminal and rod domains (Fig. 1) does not seem consistent with this truncation mutant, because other truncated dystrophin mutants have been found to be very unstable and undetectable immunohistochemically (4,6). In other cases, it has been hypothesized that the positive staining of dystrophin is the result of rescue of nonsense mutations by exon skipping or aberrant splicing (8, 26) . However, the RT-PCR-amplified product encompassing exons 70 -79 disclosed only one visible band upon agarose gel electrophoresis (Fig. 2) . In addition, both direct sequencing and sequencing after subcloning the product confirmed the presence of normal exon structure, indicating that only one mRNA was produced from the mutated gene. These observations do not support the possibility of exon-76 skipping or aberrant splicing.
Although the patient in our case harbored a Q3625X nonsense mutation, his clinical phenotype was unusually mild. Utrophin, a dystrophin-related protein, has been proposed to compensate for the function of dystrophin (27) . Therefore, overexpression of utrophin might account for the clinical phenotype seen in the present case. The expression of utrophin was studied in muscle ( Fig. 3) and was not found to be elevated in the index case in comparison with that typically seen in DMD. Therefore, enhanced expression of utrophin does not seem, to be modifying the clinical phenotype. Furthermore, the dystro- The biopsied muscle was stained for dystrophin using antibodies against the N-terminal, rod, and C-terminal domains. Staining of N-terminal and rod domains was weak, patchy, and discontinuous. In contrast, no reactive material was visualized for the C-terminal domain (patient). In unaffected individuals, all domains were clearly stained along the plasma membrane (control) but not in DMD. 
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DYSTROPHINOPATHY WITH A NEW NONSENSE MUTATION phin-dystroglycan axis was examined (Fig. 3) . Laminin ␣2, an extracellular matrix protein, stained weakly. Neither ␣-dystroglycan, an extracellular ␤-dystroglycan-binding protein, nor ␤-dystroglycan, a transmembrane dystrophin-binding protein, was stained. ␥-Sarcoglycan, a member of the sarcoglycan complex, was stained very weakly. All of these staining patterns were similar to those found in DMD (Fig. 3) , indicating no difference in the stabilization of the dystrophindystroglycan axis from that observed in DMD (Fig. 3) . Therefore, no explanation for the mild phenotype was obtained through studies of protein staining.
DISCUSSION
A novel nonsense mutation (Q3625X) in the dystrophin gene was identified in a Japanese boy who was as yet asymptomatic at the age of 8 y. Although a severe DMD phenotype would be expected to develop from his mutation type, his clinical course has been extraordinarily mild. The case has raised an important question to be answered: What is the mechanism that determines the severity of the dystrophic phenotype?
A somatic mosaic for a nonsense mutation has been shown to attenuate the clinical phenotype (28) . However, this possibility seems to be excluded in the index case for the following reasons: 1) the mutation was inherited through the mother, and 2) a single genomic clone harboring C10873T was obtained not only from his lymphocytes but also from his muscle (data not shown). To rule out this possibility unequivocally, it is necessary to examine other muscle tissues, but this has not yet been done.
Another possible attenuating mechanism would be the modification of mRNA by either exon skipping or aberrant splicing, which would remove the nonsense mutation and produce a more complete dystrophin mRNA. Examples of exon skipping have been reported in nonsense mutations identified in exons 25, 27, 29, and 72 of the dystrophin gene (7) (8) (9) (10) (11) , and aberrant splicing has been reported in intermediate dystrophinopathy (26) . In our case, however, not only the RT-PCR product of dystrophin mRNA but also subcloning sequencing disclosed the existence of only one kind of mRNA consisting of a normal exon structure (Fig. 2) . The possibility of either exon skipping or aberrant splicing thus was ruled out. Therefore, the discrepancy between genotype and phenotype could not be explained at the mRNA level.
Elevated expression of utrophin has been speculated to convert a severe phenotype to a mild one without affecting dystrophin expression (27) . However, level of utrophin expression was the same in our case as in DMD (Fig. 3) . Furthermore, the staining of proteins encompassing the dystrophindystroglycan axis was identical to that seen in DMD (Fig. 3) . These similarities show that protein-level changes do not underlie the observed phenotypic differences.
The truncated dystrophin produced in the index case seems to be unusually stable, as demonstrated by the weak but significant staining of the N-terminal and rod domains (Fig. 1) . This may be because the truncated dystrophin retains functionally important binding sites, such as actin binding sites in the N-terminal and rod domains (29, 30) , a ␤-dystroglycan binding site in the cysteine-rich domain (31) , and syntrophin and dystrobrevin binding sites and a phosphorylation site in the C-terminal domain (Fig. 4) (32-35) . In fact, it has been dem- . Dystrophin domain structure. Dystrophin consists of 3685 amino acids and is divided into four domains: the N terminus (box N), the rod (box R) and cysteine-rich (box Cy) domains, and the C terminus (box C). Three actin-binding sites have been identified in the N terminus (AB1 18 -37 amino acids, ABS3 86 -120 amino acids, and ABS2 128 -149 amino acids), and one site (amino acids 1416 -1880) has been found in the rod domain (all four sites indicated by arrowheads). In the cysteine-rich domain (amino acids 3115-326), dystrophin interacts with transmembrane ␤-dystroglycan (inverted triangle), which in turn binds to ␣-dystroglycan. Syntrophin binds to a region in the C-terminal domain (3446 -3481; open triangle), and a serine at the 3552nd residue and threonine at the 3675th residue serve as phosphorylation sites (open arrowheads). Antibodies that recognize the N-terminal, rod, and Cterminal domains react to amino acid residues 321-494, 1181-1388, and 3669 -3685, respectively (bars). The novel nonsense mutation (Q3625) is located at the end of the C-terminal domain (vertical bar). Numbers at both ends of the boxes indicate amino acid residues. The figure is not drawn to scale.
onstrated that dystrophin lacking the amino acids encoded by exons 71-78 is stable in muscle membranes of the mdx mouse, an animal model of DMD (36) . However, this hypothesis is not supported by a previous report that Q3625X, a nonsense mutation just 10 amino acids downstream of the one reported here (Q3635X), gave rise to clinically typical DMD (6) (Fig.  4) . Furthermore, examination of laminin alpha 2, ␣-and ␤-dystroglycans, and ␥-sarcoglycan disclosed no difference in their staining patterns between our case and DMD (Fig. 3) , indicating that augmented stabilization of these proteins does not contribute to the mildness of the phenotype. Clearly, further study is required to clarify these complex results.
Activation of transcription of the dystrophin gene may lead to overproduction of dystrophin mRNA. It has been proposed that an abnormality in a transcription factor(s) or in its binding site in the promoter of the dystrophin gene is a factor in phenotypic severity. In fact, mutation of the MYF6 gene results in a severe phenotype of BMD (37) . However, modifier(s) that make the phenotype mild have not been reported to date (38, 39) , although mdx mice characterized by dystrophin deficiency do not show a severe DMD phenotype (40) . We are now following up the index case, and a future study analyzing not only the dystrophin gene but also other genes may clarify the molecular mechanism explaining his mild phenotype.
